Meet The Biotech Startup Challenging Ozempic With A Fat-Burning Pill That Lets You Keep Eating
Early human data in a statement by Eolo Pharma shows it can burn fat even at rest, without appetite suppression or serious side effects. That breakthrough could reshape global obesity treatment.
Biotech Startup Pioneers First-in-Class Therapies to Treat Obesity and Metabolic Disease
Eolo Pharma is a clinical-stage biotechnology company focused on pioneering therapies for obesity and metabolic diseases. The company says it develops first-in-class small-molecule drugs that activate the body's own energy-burning pathways rather than relying on appetite suppression. Its lead candidate, SANA, is the first compound shown to safely activate creatine-dependent thermogenesis in humans, offering a novel approach to resetting metabolic health.
Don't Miss:
Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM—
'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can
Headquartered in Delaware with strong scientific roots in South America, Eolo Pharma is a spin-off of the Institut Pasteur de Montevideo, a non-profit foundation that promotes scientific and technological research. The company says it is backed by more than a decade of research into metabolic disorders and cardiometabolic complications.
Eolo Pharma's proprietary library of 60 novel chemical entities includes molecules designed to address high-burden, non-communicable diseases such as obesity, type 2 diabetes, non-alcoholic steatohepatitis, hypertension, amyotrophic lateral sclerosis, and Alzheimer's disease.
Eolo Pharma's leadership team includes CEO María Pía Garat, a biotech industry leader with a postgraduate degree from Instituto de Empresa Business School; co-founder and Chief Scientific Officer Carlos Escande, a former Mayo Clinic investigator specializing in cardiometabolic disorders; Chief Chemistry Officer Virginia Lopez, a chemist from Uruguay; and Chief Medical Officer Carlos Batthyany, who also serves as head of the Institut Pasteur de Montevideo.
Trending: $100k+ in investable assets? – no cost, no obligation.
How SANA Activates Fat Burning Without Appetite Suppression
SANA is a salicylate‑based nitroalkene compound originally developed to target inflammation, Eolo Pharma says. It was repurposed after researchers discovered it stimulates creatine‑dependent thermogenesis in white and brown fat cells.
Unlike glucagon-like peptide‑1 drugs like Ozempic, which reduce hunger, SANA boosts energy expenditure in fat tissue by turning on heat‑producing metabolic pathways at cellular level. According to Eolo Pharma, SANA protected lean mass and reduced fat more than standard salicylate or metformin in preclinical models.
"This is the first time a drug has been shown to pharmacologically activate creatine-based thermogenesis, which could lead to a novel therapeutic approach for obesity in humans," Escande said in the statement. "It opens up an entirely new therapeutic pathway for obesity and metabolic disorders."Weight Loss, Glucose Benefits, and Safety Signals
In a randomized, double‑blind, placebo‑controlled Phase 1a/b clinical trial, participants received single ascending doses or multiple ascending doses of SANA for 15 days. The trial included 17 healthy lean volunteers and 24 individuals with obesity.
According to Eolo Pharma, patients receiving SANA experienced a statistically significant reduction in body weight compared to placebo, along with improvements in fasting glucose and insulin resistance as measured by Homeostatic Model Assessment of Insulin Resistance. No serious adverse events occurred, and only mild headaches and soft stools were reported in some subjects.
A Nature Metabolism study published in June describes SANA as a first‑in‑class small molecule that activates creatine‑dependent thermogenesis in preclinical models and shows safety and early metabolic benefits in a phase 1A/B trial in humans. The authors suggest SANA as a promising therapeutic candidate for obesity, though they note that its efficacy in humans requires further confirmation in larger trials.
Read Next: The average American couple has saved this much money for retirement —?
Image: Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
APPLE (AAPL): Free Stock Analysis Report
TESLA (TSLA): Free Stock Analysis Report
This article Meet The Biotech Startup Challenging Ozempic With A Fat-Burning Pill That Lets You Keep Eating originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
9 hours ago
- New York Times
A Cancer Patient Chose Assisted Death. That Wasn't the Last Hard Choice.
The crowd was expectant when Tatiana Andia took the microphone: She was a hero to many in the room, the woman who negotiated cheaper drug prices for Colombia. But that day, at a conference for policymakers and academics on the right to health in Latin America, there was a more intimate topic she wanted to discuss. 'A year ago I was diagnosed with a terminal lung cancer,' she began, 'one that's incurable, catastrophic, all the terrible adjectives.' She gave a small laugh, acknowledging the whole thing sounded preposterous. The air in the packed conference room went still. Ms. Andia, 44, a professor and a former official in Colombia's health ministry, said she was going to speak not as an expert, but from a different perspective, one newly acquired — that of a patient. A particular health rights issue preoccupied her these days, she said: the right to death. No one, she went on, wants to talk to me about dying. She began to speak faster and faster, and her hands fluttered around her face like small birds. People in the audience looked at the floor, the ceiling, their laps. 'How come we can't talk about having a dignified death when we talk about the right to health?' she demanded. Want all of The Times? Subscribe.
Bloomberg
11 hours ago
- Bloomberg
Denmark's Economy Runs on Novo. Will the Drugmaker's Troubles Slim It Down?
Denmark's status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S. Thanks to the pharmaceutical giant's astronomical rise, the country enjoyed growth of 3.5% last year, outpacing most nations in the region. But after a series of stumbles, Novo is struggling to retain its edge in the cutthroat US weight-loss market. That, in turn, is generating concern about whether the company's troubles could lead to mass layoffs or become a drag on the broader Danish economy.
Yahoo
13 hours ago
- Yahoo
"It was kind of challenging but it was all for the good" - Luka Doncic reveals he gave up basketball to improve his conditioning for the next season
"It was kind of challenging but it was all for the good" - Luka Doncic reveals he gave up basketball to improve his conditioning for the next season originally appeared on Basketball Network. By now, the whole world has seen the transformation that Luka Doncic has made in his body in his first offseason as a Los Angeles Laker. This has not only surprised the consensus but also instilled belief that the 26-year-old superstar might just put together his best basketball season in his remarkable career so far. But ironically, what also led to Doncic's weight loss this summer wasn't basketball. In fact, the Slovenian sensation revealed that he had to be forced to stay away from it and take a whole new approach this offseason in order to achieve his goals. "I would say me and my team just tried different new things. Different food, different practices," he said. "I actually gave up playing basketball for one month, which I've never done in my life. So it was kind of challenging, but it was all good," said Doncic in his appearance on The Today's Show. Out with the old, in with the new While losing what seems to be more than 10 pounds, the 6'7" guard pursued playing other sports religiously, such as pickleball and padel. Doncic said that it helped that he played multiple sports as a kid growing up, which was why he eventually made peace with the fact that he wouldn't play basketball for a month. Instead of playing basketball, the international superstar focused on getting his diet right and placing more emphasis on weight training. Without playing basketball for the first time in years, the five-time All-Star also let his body recover completely, especially after a season that saw him miss 32 regular-season games because of a severe calf injury. This offseason, Doncic made it a point to lose weight, build muscle strength, and get right mentally. "This year, with my team, I think we did a huge step. But this is just the start, you know. I need to keep going. Can't stop," Doncic told Men's Health Magazine earlier this week. In prime position to bounce back Doncic also said he didn't lose weight to prove a point against his many critics who have long called him out for being out of shape. Instead, he did it for himself because he knows he needs to take advantage of his prime years while they're still around. It also helps that he's never been doubted the way he was last season, when not only the Dallas Mavericks traded him to the Lakers, but his early playoff exit led him to be more motivated than ever to come back stronger. "Honestly, I tried to not read much. Just tried to focus," he said about his critics. "I think I was still a pretty good basketball player back then, no matter what people say." True enough, an "out-of-shape" Doncic has averaged 28.6 points, 8.6 rebounds, and 8.2 assists thus far in his seven-year stint in the NBA. If he was able to be a top five player over the last couple of years, what more now with his change in approach in regards to his fitness? Time will eventually tell how monumental this summer would eventually end up impacting The Don's career moving story was originally reported by Basketball Network on Jul 31, 2025, where it first appeared.
